Both mixed ETA/ETB and ETA selective receptor antagonists have become established in the treatment of PAH, while NEP/ECE inhibitors such as SLV306 have promise as an alternative to receptor blockade and IRL1620 and other ETB receptor ligands have potential in improving cancer therapy. This evidence concerns the gene EDNRA and pulmonary arterial hypertension.